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Transient activation of human 
cytomegalovirus lytic gene 
expression during latency allows 
cytotoxic T cell killing of latently 
infected cells
B. A. Krishna, B. Lau, S. E. Jackson, M. R. Wills, J. H. Sinclair & E. Poole
Human cytomegalovirus (HCMV) latency in the myeloid lineage is maintained by repressive histone 
modifications around the major immediate early promoter (MIEP), which results in inhibition of the lytic 
viral life cycle. We now show that pharmacological inhibition of histone deacetylases (HDACs) relieves 
this repression of the MIEP and induces transient expression of the viral lytic immediate early (IE) 
antigens but, importantly, not full virus reactivation. In turn, these latently infected cells now become 
targets for IE-specific cytotoxic T cells (CTLs) which are present at high frequency in all normal healthy 
HCMV positive carriers but would normally be unable to target latent (lytic antigen-negative) cells. This 
approach of transiently inducing viral lytic gene expression by HDAC inhibition, in otherwise latently 
infected cells, offers a window of opportunity to target and purge the latent myeloid cell reservoir 
by making these normally immunologically undetectable cells visible to pre-existing host immune 
responses to viral lytic antigens.
Human cytomegalovirus (HCMV) causes significant morbidity and mortality in the immunocompromised and 
the immunonaïve1,2 and, as yet, an effective vaccine for the prevention of HCMV infection remains elusive3.
Like all herpesviruses HCMV persists for the life-time of the host after primary infection which is, at least in 
part, due to the consummate ability of HCMV to avoid immunosurveillance. However, this persistence is under-
pinned by the ability of the virus to establish a latent infection in certain cell types in vivo4 where viral genome 
is maintained in the absence of lytic replication. To date, all current anti-HCMV therapies target lytic virus rep-
lication; none target the latent reservoir even though reactivation from latency is a major cause of disease in 
many settings. Furthermore, there is increasing evidence associating HCMV persistence with long-term disease 
(e.g. atherosclerosis) and reactivation from latency will likely be a major contributor to this viral persistence5. 
Consequently, targeting the latent reservoir could have far reaching clinical implications.
One established site of HCMV latency in vivo are cells of the myeloid lineage, including CD14+ monocytes 
and their CD34+ progenitors6. In these cells, the viral MIEP, which drives lytic gene expression, is associated 
with repressive chromatin, which suppresses lytic transcription and maintains latent infection. Following dif-
ferentiation into macrophages or dendritic cells (DCs), however, changes in the nuclear environment result in 
chromatin-mediated activation of the viral MIEP and reactivation of lytic replication7–9. Previous work has impli-
cated a role for histone deacetylases (HDACs) in this differentiation-dependent regulation of MIEP activity in 
myeloid cells. Expression of Class I HDACs are known to decrease upon differentiation of monocytes to mac-
rophages10, consistent with the known changes in repressive and activatory histone markers on the MIEP during 
latency and reactivation in myeloid cells6,7,10–12. Similarly, other changes in cellular gene expression are known to 
occur during HCMV latency to aid latent carriage13–15 and this also includes changes in cellular miRNAs. One of 
these, miRNA hsa-miR206 which decreases during latent infection of CD34+ cells15, is known to target a class 
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II HDAC, HDAC416 and consistent with this, we now show that latent infection is associated with an increase in 
this cellular HDAC.
In the context of an inadequate immune response (either in transplant patients, the immunocompromised 
or the immunonaïve), these reactivation events can result in virus dissemination to multiple target organs and 
subsequent clinical disease1.
Importantly, we show here that the treatment of latently infected cells with the Class II -specific HDAC inhib-
itor (HDACi) MC1568 leads to the transient expression of viral lytic gene products which then makes these cells 
novel targets for pre-existing HCMV-specific CTLs, routinely present at high frequency in all immunocompetent 
virus carriers. These observations are proof of principle that the use of HDAC inhibitors can result in removal of 
latently infected cells which may be a useful novel therapeutic strategy in certain clinical settings.
Results and Discussion
Treatment of latently infected monocytes with the HDAC4 inhibitors leads to a transient induc-
tion of IE gene expression. We have previously shown that latent infection of myeloid cells results in 
major changes in cellular gene expression14 as well as changes in cellular microRNAs15. One cellular microRNA 
(miRNA) which was identified as being decreased during latency is hsa-miR-20615, which has previously been 
shown to target HDAC416. Consistent with this, latent infection of monocytes with HCMV did indeed result in 
elevated levels of HDAC4 (Fig. 1A). Furthermore, the MIEP was found to be heavily associated with HDAC4 dur-
ing latent infection (Supplementary Figure 1) suggesting a suppressive role for HDAC4 in maintaining latency.
We reasoned, therefore, that induction of histone deacetylases by latent virus may be important for the 
latency-associated repression of viral lytic gene expression and that deacetylase inhibition might impact on this 
regulation of viral gene expression during latency. Consequently, we tested whether inhibition of HDAC4 during 
latent infection had any effect on IE gene expression using the Class II-specific HDAC inhibitor MC1568, which 
is known to inhibit HDAC4 activity in vivo and in vitro17. Figure 1B–D show that treatment of latently infected 
monocytes with MC1568 (at non-toxic concentration, supplementary Figure 2A,B) resulted in a robust induction 
of IE lytic gene expression at levels of both IE protein (graphically represented in Fig. 1B and shown by immuno-
fluorescence in Fig. 1E) and RNA (Fig. 1C) which waned when drug was removed (Fig. 1D).
Figure 1. HDAC4 is increased during latency and targeted by MC1568 to induce lytic gene expression. 
5 day latent (latency) or control (mock) monocytes were analysed for actin or HDAC4 by Western blot. 
Samples were run on the same gel and autoradiographs from different exposures were cropped to show the 
HDAC4 and actin. Blots were analysed using Image J freeware in triplicate. Standard deviations are shown 
and statistical significance was determined using the Student’s t-test (A). 5 day latent monocytes (latent) or 
control (mock) monocytes were treated for 24 h with MC1568 or differentiation media. Following 24 h of 
treatment with MC1568 or 7 day differentiation, cells were stained for IE expression. Data shown (6 replicates) 
are relative to the level of IE induced following reactivation by differentiation (B) or harvesting for RT-qPCR 
analysis (C). 5 day latent monocytes were treated with MC1568 and analysed for IE expression after 24 h 
(Day 1) and then at Day 3, 5 and 7 without removal of MC1568 from the media. Data shown (6 replicates) 
are relative to the level of IE induced following reactivation by differentiation. Standard deviations are 
shown and statistical significance was determined using the Student’s t-test (D). 5 day latent monocytes were 
either untreated (latent) or treated with MC1568 for 24 h (latent plus MC1568) then fixed and stained for IE 
expression (red) with nuclei shown in blue (E).
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Interestingly, this induction of viral IE gene expression by MC1568 did not result in reactivation of the full lytic 
cycle, even after 7 days continuous treatment, as no expression of viral UL99 (pp28), a true late viral gene only 
expressed after viral DNA replication, was detected (Fig. 2A). Consistent with this, MC1568-treated monocytes 
showed no evidence of reactivation of infectious virus as detected by co-culture on indicator fibroblasts (Fig. 2B). 
Additionally, if latently infected monocytes were treated with other pan-specific HDAC inhibitors such as val-
proic acid (VPA) or trichostatin A (TSA), a transient induction of IE gene expression was also detectable (Fig. 2C). 
Interestingly, treatment of latently infected CD34+ progenitor cells with VPA and MC1568 also induced IE gene 
expression (Fig. 2D). However, consistent with reports that CD34+ cells are unresponsive to TSA18, induction of 
IE gene expression from latently infected CD34+ cells was not observed if cells were induced with TSA (Fig. 2D).
Therefore, importantly, these cells - expressing IE antigens but stalled in full reactivation -would be prime 
targets for the well established immunodominant IE-specific T cell responses known to be at high frequency in 
normal HCMV carriers.
Transient expression of lytic IE antigen in HDAC-inhibitor treated cells opens a window of 
opportunity to target latent cells with IE-specific CTLs. Between 0.5–10% of total circulating 
CD8+ CTLs in healthy HCMV seropositive donors are specific for the viral major IE lytic gene19. However, 
these IE-specific T cells do not target latently infected (lytic antigen negative) cells; consistent with the fact that 
latent infection is not cleared despite such high populations of functional IE-specific CTLs. We predicted, how-
ever, that treatment of latently infected cells with MC1568 should make them become IE-specific CTL targets. 
Figure 3A shows that co-culture of MC1568-treated latent monocytes with IE-specific T cell clones, but not irrel-
evant EBV-specific T cells, resulted in a robust decrease in the number of monocytes positive for IE gene expres-
sion. Consistent with the mediation of this effect through T cell effector function, MC1568-treated monocytes 
also resulted in increased IFN-gamma responses by HCMV-specific T cells to levels comparable to monocytes 
induced to reactivate by full differentiation (Fig. 3B). Perhaps more importantly, MC1568-treated monocytes, 
after co-culture with IE-specific CTLs, showed a robust reduction in their ability to reactivate virus after standard 
differentiation as detected by re-infection of co-cultured indicator fibroblasts (Fig. 3C).
Although the data, so far, suggest that the IE-specific CTLs were recognising and killing the latently infected 
cells, which had been induced to express IE antigens by HDAC inhibitor treatment, it is possible that this removal 
of monocytes expressing IE antigen resulted from CTL-mediated repression of IE gene expression and that 
these monocytes still carried reactivatable virus. In order to confirm that the disappearance of monocytes tran-
siently expressing IE was due to T cell killing, rather than perhaps re-repression of IE gene expression, we con-
firmed the expression of CD107a (LAMP-1 an indication of cytotoxic T cell degranulation and part of the CTL 
Figure 2. MC1568 does not cause full reactivation and pan-HDAC inhibitors also induce IE expression. 
5 day latent (latent) monocytes were left untreated, treated with MC1568 for 7 days or differentiated. RNAs 
encoding viral IE, UL99 (pp28), UL138 and cellular GAPDH were analysed in duplicate by RT-qPCR and 
standard deviations are shown (A). Alternatively, 5 day latent monocytes (latent) were treated with MC1568 
or differentiated and then co-cultured with fibroblasts to analyse infectious foci formation (B). 5 day latent 
monocytes were also treated over 1–7 days with VPA or TSA and analysed for IE expression. Data shown (6 
replicates) are relative to the level of IE induced following reactivation by differentiation (C). Additionally, 5 day 
latent CD34+ cells (latent) were treated with MC1568, TSA or VPA for 24h (Day 1) and levels of IE expression 
were also analysed at days 2, 5 and 7 without removal of the drugs. Data are shown (6 replicates) relative to 
IE expression induced by differentiation of CD34+ cells. Mock represents IE expression in uninfected cells. 
Standard deviations are shown and statistical significance was determined using the Student’s t-test (D).
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killing mechanism) in these IE-specific T cells after surveillance of MC1568-treated latent monocytes (Fig. 3D). 
Figure 3D shows that CD107a was indeed upregulated in T cells which had been co-cultured with latent mono-
cytes that had been induced to express IE by MC1568 and, therefore, these IE-specific CTLs were not only recog-
nising but also released their cytotoxic granules, an indication of killing activity. Taken together, these data clearly 
showed that HDAC inhibition results in transient induction of viral IE gene expression in experimentally latent 
monocytes, resulting in them becoming temporarily visible to IE-specific CTLs.
However, a key question is whether drug treatment permits naturally latently infected cells in the periph-
eral blood of healthy donors to become targetable by blood resident HCMV-specific CTLs. To address this we 
carried out analyses on total peripheral blood mononuclear cells (PBMC) from two seropositive individuals to 
allow assessment of the effectiveness of MC1568 in clearing naturally latent HCMV from the peripheral blood. 
Figure 4A shows that naturally latent cells do not produce infectious virus (column a), as expected (shown by a 
lack of infectious foci on indicator fibroblasts). Again, as expected, latent cells induced to differentiate, reactivate 
infectious virus (column c) but this reactivation is ablated in the presence of T cells (column d). This argues that 
the T cells in the PBMC compartment are able to detect differentiation-dependent virus reactivation. Consistent 
with the fact that MC1568 treatment does not induce full virus reactivation in latently infected monocytes, 
HDACi treatment showed no virus production regardless of whether they were cultured with or without autol-
ogous T cell-containing PBMCs (columns e and f). However, autologous T cell-containing PBMCs completely 
ablate the ability of these transiently IE1-expressing latent cells to reactivate endogenous latent virus after their 
subsequent differentiation (columns g and h). Repeating the analysis using T cell-depleted PBMCs confirmed that 
the T cell population in these PBMCs were effecting this reduction in latent cells capable of reactivating infectious 
virus (Fig. 4B).
Figure 3. Treatment of experimentally latent monocytes with MC1568 or VPA reduces reactivation 
mediated by IE-specific T cells. Monocytes latently infected with an IE-GFP tagged virus for 5 days were 
treated with MC1568 and cultured with IE or EBV-specific T cells, following which, monocytes expressing 
IE-GFP were counted. The graph shows numbers of IE-GFP expressing monocytes relative to IE expression 
in the absence of T cells (A). Alternatively, 5 day latent monocytes (untreated) were treated with MC1568 or 
induced to differentiate (differentiated), cultured with IE-specific T cells and analysed by IFN-gamma ELISpot. 
The graph represents the number of spot forming units (SFUs) above background (B). Additionally, 5 day 
latent monocytes with (+ ) or without (− ) MC1568 treatment were co-cultured without (no T cells) or with IE-
specific T cells or EBV-specific T cells. After this, monocytes were reactivated by differentiation and infectious 
foci quantified by co-culture on indicator fibroblasts (C). 5 day latent monocytes (latent) monocytes were left 
untreated (latent) or treated with MC1568 (+ MC1568) and co-cultured with IE or EBV-specific T cells, then 
analysed for CD107a expression. The graph represents fold induction of CD107a expression in IE1-specific T 
cells after presentation to latently infected cells treated with MC1568 compared to untreated latently infected 
cells. Values were corrected to CD107a expression following presentation of the same MC1568 treated and 
untreated latent cells to EBV specific (irrelevant) T cells (D).
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Taken together, these data argue that pre-existing autologous IE-specific T cells in the peripheral blood com-
partment of healthy HCMV carriers are able to target and purge naturally latently infected monocytes after these 
monocytes have been treated to induce IE expression transiently with HDAC inhibitors.
Our view is that such novel immunotherapeutic strategies could lend themselves to, for example, the treat-
ment of stem cell donations from HCMV seropositive donors to reduce latent load prior to engraftment but, as a 
number of HDAC inhibitors are already in clinical use, could also be used in donors prior to donation.
Materials and Methods
Viruses, cells and latency. Cell isolations and establishment of experimental latency using HCMV TB40E 
or IE2-EYFP-tagged TB40E have been described previously14. For the studies of natural latency, approximately 
5 × 108 CD14+ monocytes were isolated as described14 but using apheresis cones from seropositive individuals. 
Frozen CD34+ progenitor cells were obtained from Lonza.
Quantification of experimental and natural latency. All assays quantifying IE reactivation in response 
to treatments were normalised to the number of IE positive cells following reactivation by differentiation of 
CD14+ or progenitor cells into dendritic cells as described previously20. In our experiments, experimental latency 
was routinely established in approximately 20% of cells. Reactivation of IE expression by differentiation varied 
from 0.25–25% of these latent cells. Therefore, in a well of 105 cells, the number of IE positive cells following reac-
tivation routinely ranged from 5 to 500 IE expressing cells per well between experiments. Consequently, data were 
normalised to numbers of IE-expressing cells after differentiation.
For natural latency, differentiation of approximately 106 cells routinely resulted in 2–10 IE positive foci of 
infection and these numbers are directly graphically represented. Unless otherwise stated, each experiment was 
carried out a minimum of two times with at least duplicate samples.
Statistics. Error bars represent standard deviation and P values were determined using the Student’s t-test. 
Values are represented by the standard asterisk system where P < 0.05* is statistically significant; P < 0.01** is of 
medium significance and P < 0.001*** is statistically highly significant.
Western blotting. Western blotting was carried out as described previously21 with the primary antibodies 
rabbit anti-actin (Abcam) and mouse anti-HDAC4 (Cell Signalling).
Immunofluoresence. Cells were fixed and stained as described previously22. Cells were stained with mouse 
anti-IE (Argene 11-003) followed by goat anti-mouse (Alexafluor 633 or 488, Molecular Probes) with Hoechst 
nuclear stain. Alternatively, if cells were infected with YFP-IE TB40E23, nuclei were stained in live cells with 
Hoechst.
T cell co-culture. CD14+ monocytes were plated at 1 × 105 per well of a 96 well plate and then co-cultured 
in X-Vivo 15 supplemented with 2 mM L-Glutamine with donor-matched (HLA-A2) EBV or HCMV-specific 
CD8+ T cells at a ratio of 5:1. The number of HCMV IE-expressing monocytes were enumerated over several 
days as indicated.
Figure 4. Treatment of naturally latent monocytes with MC1568 or VPA reduces reactivation. Monocytes 
from PBMCs of HCMV seropositive individuals were isolated by plastic adherence. Adherent monocytes were 
left untreated (no treatment, columns a and b), differentiated to reactivate virus (differentiated, columns c and d), 
treated with MC1568, (columns e and f) and cultured in the presence (+ ) or absence (− ) of the residual PBMCs 
(after monocyte depletion). Additionally, wells of MC1568-treated monocytes, after removal of T cells, were 
also subsequently induced to differentiate (columns g and h). In all cases, any reactivated virus was quantified 
by fibroblast co-culture and staining for IE positive foci (A). Finally, CD14+ monocytes from PBMCs of two 
HCMV seropositive individuals were isolated, adhered to plastic and left untreated (none), treated with MC1568 
or VPA for 24 h. The PBMCs left after CD14+ isolation were either left untreated (CD14+ depleted PBMC) or 
further depleted of T cells by CD3+ positive selection (CD14+ /CD3+ depleted PBMCs). Subsequently, PBMCs 
were removed by washing and cells were differentiated and any reactivated virus was quantified by fibroblast co-
culture and staining for IE foci (B). Standard deviations are shown and statistical significance was determined 
using the Student’s t-test.
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ELISpot. ELISPOT plates were prepared, coated and blocked according to manufacturer’s instruction (eBio-
science). CD14+ monocytes, isolated directly ex vivo were isolated from total PBMC by magnetic activated cell 
sorting (MACS), were co-cultured with donor-matched IE-specific CD8+ T cells in 100 μl RPMI-10 per well (of 
a 96 well Multiscreen IP sterile plate (Millipore, UK)). Plates were incubated for 48 hours at 37 °C in 5% CO2, and 
developed according to manufacturer’s instructions. Plates were read using an ELISPOT plate scanner (ELISPOT 
Reader System, AID) and spots enumerated using ImageJ (National Institutes of Health).
CD107a assay. Cells were co-incubated with IE-specific CD8+ T cell lines or EBV-specific T cell lines over-
night in the presence of CD107a Alexa fluor 647, 5 μg/ml Brefeldin A and 2μM Monensin (all from BioLegend) at 
37 °C in a humidified CO2 atmosphere. CD8+ T cells were harvested and washed, then stained with a combina-
tion of surface antibodies (Supplementary Table 1A) and LIVE/DEAD Fixable Yellow Dead cell stain (Invitrogen) 
at 4 °C. Cells were fixed and permeabilised using FIX&PERM (ADG, Kaumberg, Austria) and stained intracel-
lularly with antibodies (Supplementary Table 1B) at 4 °C in the dark. Samples were washed and fixed in a final 
1% paraformaldehyde solution and acquired on a BD LSR Fortessa cytometer using FACSdiva software (BD 
Biosciences). Data was analysed using FlowJo software (Treestar). Responding CD8+ T cell populations were 
identified by the expression of CD107a above the background expression observed in the mock infected control 
following elimination of doublets, removal of monocytes and B cells and dead cells from the analysed population.
Drug treatments. MC1568 (Sigma) was tested for cytotoxicity (Supplementary Figure 1) and used at 
the non-toxic concentration of 1000nM. Trychostatin A (TSA) (New England Biolabs), valproic acid (VPA) 
(Miltenyi) were made up as directed by the manufacturer and used at the concentrations indicated
RT-qPCR. RNAs were isolated using the miRNeasy mini-kit and amplified using the Quantitect virus + ROX 
virus kit (Qiagen). The viral IE transcript was amplified alongside the housekeeping transcript GAPDH using the 
following primers and probes: IE: CAAGAACTCAGCCTTCCCTAAGAC and TGAGGCAAGTTCTGCAATGC 
with the probe [FAM]CCAATGGCTGCAGTCAGGCCATG[TAM] and GAPDH GGAAGCTTGTCATCAATG 
and CCCCACTTGATTTTGGAG with the probe [JOE]ATCACCATCTTCCAGGAGCGAG[BHQ1]. Viral 
transcript UL138 was detected with primers CGCTGTTTCTCTGGTTAG and CAGACGATACCGTTTCTC 
with probe [Cy5]CCGACGACGAAGACGATGAAC[BHQ2] and viral transcript UL99 (pp28) with 
the primers CGAACTCTGCAAACGAATA and GAGGGATGTTGTCGTAGG with the probe [Cy3]
CGTAGAGACACCTGGCGACC[BHQ2]. Samples were analysed with an ABI 7500 Fast Real Time machine 
using MicroAmp Fast Optical 96 well reaction plates using the RT parameters: 50 °C for 20 min followed by heat 
inactivation 95 °C for 5 min then PCR steps: 50 cycles, 95 oC for 15 s and 60 oC for 45 s. Data were accrued from 
reactions carried out in the presence and absence of RT and the minus RT values subtracted from the plus RT 
samples to obtain the RNA levels. All primers were tested against a standard curve to allow comparison between 
samples.
ChIP and qPCR. Chromatin immunopreciptition assays were carried out as described previously24. 
Lysates were incubated with either an antibody to HDAC4 (1 μg/ml Santa Cruz Biotechnology) or the 
isotype-matched control (1μg/ml). Following elution of immunoprecipitated DNA, the MIEP was ampli-
fied by qPCR using the Quantitect virus + ROX virus kit (Qiagen) with the following primers and probe: 
CCAAGTCTCCACCCCATTGAC and GACATTTTGGAAAGTCCCGTTG with the probe [FAM]
TGGGAGTTTGTTTTGGCACCAAA[TAM] and with the following PCR parameters: 50 cycles. 95 oC for 15 s 
and 60 oC for 45 s.
Cytotoxicity assays. To analyse the levels of cell death, cells were stained directly with trypan blue in PBS 
(a live dead discriminator). Alternatively, the viability of cells was determined using the LIVE/DEAD Fixable 
dead cell stain kit (Invitrogen, Molecular probes) and analysed by FACS.
Ethics statement. All human samples were obtained under ethical approval and after approval of protocols 
from the Cambridgeshire 2 Research Ethics Committee (REC reference 97/092) and that these protocols were 
conducted in accordance with the Declaration of Helsinki. Informed written consent was obtained from all of 
the volunteers included in this study prior to providing blood samples and all experiments were carried out in 
accordance with the approved guidelines.
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